Novo Nordisk A/S held its Annual General Meeting on March 27, 2025, approving key resolutions including a final dividend of DKK 7.90 per share and reporting over 45 million beneficiaries from its diabetes and obesity innovations in 2024. The meeting also confirmed re-elections for the Board of Directors and authorized share repurchases.